Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy.
Eugene E WrightMatthew S D KerrIgnacio J ReyesYelena NabutovskyEden M MillerPublished in: Diabetes spectrum : a publication of the American Diabetes Association (2021)
Prescription of the flash CGM system was associated with significant reductions in A1C in patients with type 2 diabetes treated with basal insulin or noninsulin therapy. These findings provide evidence for expanding access to flash CGM within the broader population of people with type 2 diabetes.